These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 28197367)

  • 1. Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.
    Kailayangiri S; Altvater B; Spurny C; Jamitzky S; Schelhaas S; Jacobs AH; Wiek C; Roellecke K; Hanenberg H; Hartmann W; Wiendl H; Pankratz S; Meltzer J; Farwick N; Greune L; Fluegge M; Rossig C
    Oncoimmunology; 2017; 6(1):e1250050. PubMed ID: 28197367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-G and HLA-E Immune Checkpoints Are Widely Expressed in Ewing Sarcoma but Have Limited Functional Impact on the Effector Functions of Antigen-Specific CAR T Cells.
    Altvater B; Kailayangiri S; Pérez Lanuza LF; Urban K; Greune L; Flügge M; Meltzer J; Farwick N; König S; Görlich D; Hartmann W; Rossig C
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
    Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.
    Englisch A; Altvater B; Kailayangiri S; Hartmann W; Rossig C
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28313. PubMed ID: 32729251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G.
    Spurny C; Kailayangiri S; Altvater B; Jamitzky S; Hartmann W; Wardelmann E; Ranft A; Dirksen U; Amler S; Hardes J; Fluegge M; Meltzer J; Farwick N; Greune L; Rossig C
    Oncotarget; 2018 Jan; 9(5):6536-6549. PubMed ID: 29464090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells.
    Zhuang X; Long EO
    Front Immunol; 2022; 13():840844. PubMed ID: 35585985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
    Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
    Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
    Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
    Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-free CRISPR knock-in of a chimeric antigen receptor into
    Shankar K; Zingler-Hoslet I; Shi L; Katta V; Russell BE; Tsai SQ; Capitini CM; Saha K
    bioRxiv; 2024 Feb; ():. PubMed ID: 38405747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.
    Jamitzky S; Krueger AC; Janneschuetz S; Piepke S; Kailayangiri S; Spurny C; Rossig C; Altvater B
    Pediatr Blood Cancer; 2015 Nov; 62(11):1979-85. PubMed ID: 26131572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 Inhibition in Ewing Sarcoma Upregulates G
    Kailayangiri S; Altvater B; Lesch S; Balbach S; Göttlich C; Kühnemundt J; Mikesch JH; Schelhaas S; Jamitzky S; Meltzer J; Farwick N; Greune L; Fluegge M; Kerl K; Lode HN; Siebert N; Müller I; Walles H; Hartmann W; Rossig C
    Mol Ther; 2019 May; 27(5):933-946. PubMed ID: 30879952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
    Mitwasi N; Feldmann A; Arndt C; Koristka S; Berndt N; Jureczek J; Loureiro LR; Bergmann R; Máthé D; Hegedüs N; Kovács T; Zhang C; Oberoi P; Jäger E; Seliger B; Rössig C; Temme A; Eitler J; Tonn T; Schmitz M; Hassel JC; Jäger D; Wels WS; Bachmann M
    Sci Rep; 2020 Feb; 10(1):2141. PubMed ID: 32034289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-Expression of an IL-15 Superagonist Facilitates Self-Enrichment of GD
    Bodden M; Häcker A; Röder J; Kiefer A; Zhang C; Bhatti A; Pfeifer Serrahima J; Ullrich E; Kühnel I; Wels WS
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
    Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
    J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
    Oei VYS; Siernicka M; Graczyk-Jarzynka A; Hoel HJ; Yang W; Palacios D; Almåsbak H; Bajor M; Clement D; Brandt L; Önfelt B; Goodridge J; Winiarska M; Zagozdzon R; Olweus J; Kyte JA; Malmberg KJ
    Cancer Immunol Res; 2018 Apr; 6(4):467-480. PubMed ID: 29459477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.
    Genßler S; Burger MC; Zhang C; Oelsner S; Mildenberger I; Wagner M; Steinbach JP; Wels WS
    Oncoimmunology; 2016 Apr; 5(4):e1119354. PubMed ID: 27141401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.
    Kailayangiri S; Altvater B; Meltzer J; Pscherer S; Luecke A; Dierkes C; Titze U; Leuchte K; Landmeier S; Hotfilder M; Dirksen U; Hardes J; Gosheger G; Juergens H; Rossig C
    Br J Cancer; 2012 Mar; 106(6):1123-33. PubMed ID: 22374462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer.
    Ao X; Yang Y; Li W; Tan Y; Guo W; Ao L; He X; Wu X; Xia J; Xu X; Guo J
    J Immunother; 2019 Oct; 42(8):284-296. PubMed ID: 31261167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.